Liquid biopsy as a follow‐up tool: Comment on longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors
Authors:
- Umberto MalapelleUmberto Malapelle
- Christian RolfoCRChristian Rolfo
- on behalf of the International Society of Liquid Biopsy (ISLB)O(on behalf of the International Society of Liquid Biopsy (ISLB)
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLCJournal of Thoracic Oncology, 2018
- Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled AnalysisCurrent Cancer Drug Targets, 2018
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutationsAnnals of Oncology, 2016
- Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)Oncotarget, 2016
- Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung AdenocarcinomaJournal of Thoracic Oncology, 2015
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNAClinical Cancer Research, 2014
- EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non–small cell lung carcinoma patientsCancer Cytopathology, 2013
- The Importance of a Satisfactory Biopsy for the Diagnosis of Lung Cancer in the Era of Personalized TreatmentCurrent Oncology, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012